Daniels Eric Joseph 4

What Happened

• Eric Daniels, Chief Development Officer of Kiora Pharmaceuticals (KPRX), received equity awards on 2026-03-06: 6,533 restricted shares (grant A) and a derivative grant representing 13,067 shares (reported as A, a stock option). Both entries show $0 cash paid on the Form 4. Total awards equal 19,600 shares granted/covered by the filing.
• The restricted stock and option are grants (not sales or exercises). No immediate sale or exercise was reported.

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (filed within the standard two-business-day window).
• Reported acquisition price: $0.00 for both the restricted shares and the derivative/option.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote F1 (restricted stock): 6,533 shares vest one‑third on each of April 1, 2027, 2028 and 2029, subject to continued service.
• Footnote F2 (option/derivative): option becomes exercisable one‑third on April 1, 2027; remaining balance vests monthly on the first day of each calendar month thereafter for two years, subject to continued service.
• Transaction codes: A = Award/Grant (no indication of a cashless exercise or immediate sale).

Context

• These are standard compensation grants under Kiora's 2024 Equity Incentive Plan and do not represent a purchase or sale in the open market. Grants reflect compensation/retention and are subject to multi-year vesting; they are not an immediate liquidity event.